Opexa Therapeutics opexatherapeutics.com


Public list: BIO 2016 (619) Pharma Startups (4732) Cancer Therapeutics (1137)

Opexa Therapeutics is a publicly-traded cellular therapy company located in the Woodlands, TX (outside of Houston) with two proprietary, broad technical therapeutic platforms: T-cell vaccination and autologous stem cell therapy. Opexa Therapeutics is developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis, cardiovascular disease, and diabetes.

Opexa Therapeutics is a publicly-traded cellular therapy company located in the Woodlands, TX (outside of Houston) with two proprietary, broad technical therapeutic platforms: T-cell vaccination and autologous stem cell therapy. Opexa Therapeutics is...Show all

Company (IPO / Went public)

Phone: 281-272-9331

Fax: 281-272-1088

2635 N Crescent Ridge Drive

The Woodlands, 77381
Texas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Opexa Therapeutics $87M Jun 16, 2006
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Opexa Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Bayhill Therapeutics

San Mateo, California, United States
Dead / InactiveBayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without effecting normal protective immune system cells. BHT-DNA is being studied in a Phase II trial for multiple ...Show allLogin to see details

Pharmasset

Princeton, New Jersey, United States
AcquiredPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset's research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. In January 2012, Pharm...Show allLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Rheumatoid arthritis t cell vaccine Jun 27, 2007 Jan 14, 2014 Patent
Isolation and identification of cross-reactive t cells Aug 19, 2009 Jul 05, 2011 Patent
Compositions and methods for treating b cell mediated autoimmune disorders Sep 04, 2015 Application
Potency assay for therapeutic agents Jan 23, 2015 Application
Methods of t cell epitope profiling, making t cell compositions, and treating diseases Dec 19, 2014 Application